Effect of Genzyme’s LEMTRADA maintained in patients beyond two-year pivotal MS studies
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
List view / Grid view
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
27 February 2013 | By Genzyme
Sanofi and its subsidiary Genzyme announced today that Genzyme has received a Company Award from EURORDIS...
29 January 2013 | By Sanofi
“Today’s FDA approval of KYNAMRO is great news..."
28 January 2013 | By Sanofi
Genzyme also reports very encouraging early launch indicators for AUBAGIO® (teriflunomide) in U.S.
14 December 2012 | By Sanofi
"We are disappointed by the Committee's recommendation..."
28 November 2012 | By Citigate Dewe Rogerson Ltd
Genzyme appointed Brendan Martin as General Manager for UK and Ireland...
31 October 2012 | By
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications...
12 October 2012 | By Sanofi
Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS...
9 October 2012 | By Genzyme
New data from Genzyme’s clinical development programs...
12 September 2012 | By Sanofi
AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing Multiple Sclerosis...
12 June 2012 | By Sanofi
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare...
3 May 2012 | By Sanofi
FDA and the EMA approve 2nd operation for filling and finishing product...
20 April 2012 | By Sanofi
Full CARE-MS II results for Alemtuzumab to be unveiled...
18 January 2012 | By Sanofi
Sanofi & Genzyme announced that the EMA has approved its manufacturing plant in Framingham....
14 November 2011 | By Sanofi
The Phase lll CARE-MS ll trial met both of its co-primary endpoints...